Prior to the mid-1960s, advanced-stage Hodgkin disease was treated with single-agent chemotherapy, with fairly dismal long-term survival and cure rates.
While MOPP was remarkably successful in curing advanced Hodgkin lymphoma, its toxicity remained significant.